Eledon Pharmaceuticals

NAQ:ELDN · US28617K1016

BiotechnologySmall

360° View

Value25

Price/Sales—

Price/Earnings58

Price/Book22

Dividend Yield1

Growth16

Revenue Growth—

Profit Growth36

Capital Growth8

TSR 52w49

Safety65

Leverage86

Liquidity62

Refinancing24

Combined27

Sentiment43

Analyst Opinions100

Pro Holdings35

Opinion Changes9

Market Pulse49

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQCM

Employees34

Websiteeledon.com

ISINUS28617K1016

Last UpdateApr 2, 2026

Index & Theme

Chronic DiseasesImmunologyNephrologyNeurologyEndocrinologyDiabetesBiotechnologyHealth CareMedicalPharmaceutical

Description

Eledon Pharmaceuticals, Inc. (Eledon) is a clinical stage biotechnology company. The company is using its immunology expertise in targeting the CD40 Ligand (‘CD40L’) pathway to develop therapies to protect transplanted organs and prevent rejection,…

Analysis

Eledon Pharmaceuticals's 360° View rank of 16 places it among the weakest overall — better than 16% of its true peers.

It's lagging on growth (16) and expensive versus peers (25). On safety it is financially sound (65), and the market shows muted sentiment (43). Taken together, its Combined rank of 27 reads as below its peer average.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Eledon Pharmaceuticals with its peers

AnaptysBio

NSQ:ANAB

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Equillium

NAQ:EQ

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Fulcrum Therapeutics

NMQ:FULC

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

LB Pharmaceuticals

NMQ:LBRX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

CalciMedica

NAQ:CALC

—

CountryUSA

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

EyePoint

NMQ:EYPT

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →